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Background: Intracranial aneurysm (IA) is a socially important disease due to its high incidence in the general
public and the severity of resultant subarachnoid hemorrhage that follows rupture. Despite the social importance of
IA as a cause of subarachnoid hemorrhage, there is no medical treatment to prevent rupture, except for surgical
procedures, because the mechanisms regulating IA formation are poorly understood. Therefore, these mechanisms
should be elucidated to identify a therapeutic target for IA treatment. In human IAs, the presence of inflammatory
responses, such as an increase of tumor necrosis factor (TNF)-alpha, have been observed, suggesting a role for
inflammation in IA formation. Recent investigations using rodent models of IAs have revealed the crucial role of
inflammatory responses in IA formation, supporting the results of human studies. Thus, we identified nuclear factor
(NF)-kappaB as a critical mediator of inflammation regulating IA formation, by inducing downstream pro-inflammatory
genes such as MCP-1, a chemoattractant for macrophages, and COX-2. In this study, we focused on TNF-alpha signaling
as a potential cascade that regulates NF-kappaB-mediated IA formation.
Results: We first confirmed an increase in TNF-alpha content in IA walls during IA formation, as expected based on
human studies. Consistently, the activity of TNF-alpha converting enzyme (TACE), an enzyme responsible for TNF-alpha
release, was induced in the arterial walls after aneurysm induction in a rat model. Next, we subjected tumor necrosis
factor receptor superfamily member 1a (TNFR1)-deficient mice to the IA model to clarify the contribution of TNF-alpha-
TNFR1 signaling to pathogenesis, and confirmed significant suppression of IA formation in TNFR1-deficient mice.
Furthermore, in the IA walls of TNFR1-deficient mice, inflammatory responses, including NF-kappaB activation,
subsequent expression of MCP-1 and COX-2, and infiltration of macrophages into the IA lesion, were greatly suppressed
compared with those in wild-type mice.
Conclusions: In this study, using rodent models of IAs, we clarified the crucial role of TNF-alpha-TNFR1 signaling in the
pathogenesis of IAs by inducing inflammatory responses, and propose this signaling as a potential therapeutic target
for IA treatment.
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Intracranial aneurysm (IA) is a lesion with a regional
bulging of intracranial arteries, usually located at bifur-
cation sites. IA is a common disease in the general pub-
lic, with a prevalence of 1–5 percent [1], and is a major
cause of subarachnoid hemorrhage [2]. Subarachnoid* Correspondence: tomoaoki@kuhp.kyoto-u.ac.jp
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unless otherwise stated.hemorrhage continues to be responsible for high mor-
tality and morbidity rates, despite advances in medical
technologies [3], and therefore, the prevention of pre-
existing IA rupture is imperative. Furthermore, IAs have
a remarkable negative impact on society, not only due to
death or complications resulting from subarachnoid he-
morrhage, but also due to the anxiety associated with
potential rupture. Indeed, a recent report demonstrated
that the quality of life of patients with IAs was signi-
ficantly limited [4] even if IAs did not rupture. Impor-
tantly, treatment of IAs was also shown to restore the
social activity of these patients. In this sense, the treat-
ment of IAs is socially important. However, to date,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ical treatment to prevent the rupture of IAs. Given the
severity and negative social impact of a resulting sub-
arachnoid hemorrhage after rupture, the mechanisms
underlying IA formation and rupture should be investi-
gated to develop a novel medical treatment for IAs.
Various studies using human IA specimens have re-
vealed the involvement of active inflammatory responses
in IA lesions, such as the expression of inflammatory cy-
tokines, the infiltration of inflammatory cells into lesions,
and the positive linkage of inflammatory-gene polymor-
phisms with IAs [5-9]. Furthermore, recent experiments
using animal models of IAs support the interpretation of
human studies that inflammatory responses in intracranial
arterial walls regulate IA formation and progression.
Among factors regulating inflammatory processes, we
have revealed a critical role for nuclear factor (NF)-kappaB
in the pathogenesis of IA formation. NF-kappaB is ac-
tivated in endothelial cells and macrophages in IA
walls during IA formation, and NF-kappaB p50 sub-
unit deficiency or inhibition by decoy oligonucleotides
or compounds with anti-NF-kappaB effects significantly
suppresses IA formation and progression in rodent mo-
dels [10,11]. In addition, the inhibition of NF-kappaB
activation in IA walls suppresses the expression and
production of downstream pro-inflammatory factors regu-
lating IA formation, such as matrix metalloproteinase-9
(MMP-9), monocyte chemoattractant protein-1 (MCP-1),
and interleukin-1 beta (IL-1beta) [10,11]. However, be-
cause NF-kappaB mediates many physiological processes,
it is not a suitable therapeutic target. Indeed, despite the
crucial role of NF-kappaB in various inflammatory dis-
eases, no anti-NF-kappaB therapy has been established.
Tumor necrosis factor (TNF)-alpha is a cytokine that
can strongly activate NF-kappaB, and TNF-alpha signal-
ing has been implicated in the pathogenesis of human
IAs. For example, increased TNF-alpha mRNA expres-
sion in lesions as determined by reverse transcription
PCR (RT-PCR) [6], increased plasma TNF-alpha concen-
tration in patients with IAs [12], and the possible linkage
of TNF-alpha signaling with IA rupture in whole-genome
expression profile analysis [9], have been reported. Fur-
thermore, a positive correlation between single nucleotide
polymorphisms in the TNF-alpha gene and increased risk
of incidence and rupture, has been identified [13,14].
Based on these findings, in this study, we examined the
contribution of TNF-alpha signaling to IA formation
using tumor necrosis factor receptor superfamily member
1a (TNFR1)-deficient mice.
Materials and methods
Rodent IA models and histological analysis of induced IA
All of the following experiments, including animal care
and use, complied with the National Institute of Health’sGuide for the Care and Use of Laboratory Animals and
were approved by the Institutional Animal Care and
Use Committee of Kyoto University Graduate School
of Medicine.
Male Sprague–Dawley rats were purchased from Japan
SLC (Shizuoka, Japan). TNFR1-deficient mice were pur-
chased from The Jackson Laboratory (Bar Harbor, ME,
USA). Animals were maintained on a light/dark cycle of
14 h/10 h, and had free access to chow and water. To in-
duce IA, under general anesthesia by intraperitoneal in-
jection of pentobarbital sodium (50 mg/kg), 7-week-old
male rats or mice were subjected to ligation of the left
carotid artery and systemic hypertension, induced by the
combination of salt overloading and ligation of the left
renal artery. This procedure is designed to increase he-
modynamic stress, the trigger of IA formation [15-17],
on the bifurcation site of intracranial arteries [18-20].
Immediately after the surgical procedure, animals were
fed a special chow containing 8% sodium chloride and
0.12% 3-aminopropionitrile (Tokyo Chemical Industry,
Tokyo, Japan), an inhibitor of lysyl oxidase that catalyzes
the cross-linking of collagen and elastin. IA induction at
the right anterior cerebral artery (ACA) and olfactory
artery (OA) bifurcation, the contralateral side of the ca-
rotid ligation was assessed at times indicated in the corre-
sponding Figure legends [18-20]. In histological analyses,
after measurement of systemic blood pressure by the tail-
cuff method, animals were deeply anesthetized by intra-
peritoneal injection with a lethal dose of pentobarbital
sodium, and transcardially perfused with 4% parafor-
maldehyde. The right ACA-OA bifurcation including
the IA lesion was then stripped, and serial frozen sections
were made. The IA lesion was defined by the disruption of
the internal elastic lamina, as visualized by Elastica van
Gieson staining.
Immunohistochemistry
Immunohistochemical analyses were performed as previ-
ously described [19]. Briefly, at the indicated period after
aneurysm induction, 5-um-thick frozen sections were
made as described above. After blocking with 3% donkey
or goat serum (Jackson ImmunoResearch, Baltimore,
MD, USA), slices were incubated with primary anti-
bodies followed by incubation with fluorescence-labeled
secondary antibodies (Jackson ImmunoResearch). Fi-
nally, fluorescent images were acquired through a con-
focal fluorescence microscope system (CTR6500, Leica
Microsystems, Tokyo, Japan). Representative images from
at least 3 independent samples are shown in Figures 1
and 2. The relative intensity of positive staining in IA
walls from each experiment was measured by imaging
software and statistically analyzed.
The following primary antibodies were used: mouse
monoclonal anti-smooth muscle alpha actin antibody
Figure 1 Increased TNF-alpha content in the IA lesion. (A) Immunohistochemistry to detect TNF-alpha in IA walls located at right anterior
cerebral artery-olfactory artery bifurcations in a rat model. Immunohistochemistry to detect TNF-alpha in control arterial and IA walls from
rats, 3 months after aneurysm induction, is shown. The white arrow and arrow head indicate positive staining in endothelial cells and outer
membranes, respectively. The star in the left panel indicates the media of arterial walls. Bar = 50 um. In the right panel, the relative intensities
of positive signals in IA walls from the left panel are shown. n = 3 in each group, and *indicates p < 0.05. All bars indicate the mean ± SEM.
(B) Increased TNF-alpha content in intracranial arteries after aneurysm induction. TNF-alpha content was analyzed by multi-suspension array using
intracranial arteries from rats at indicated time points after aneurysm induction. n = 6 in each group. All bars indicate the mean ± SEM, and
*indicates p < 0.05. M; month after aneurysm induction. (C) Enhanced tumor necrosis factor alpha converting enzyme (TACE) activity in intracranial
arteries after aneurysm induction. TACE activity was measured as explained in the Methods section. n = 4 in both groups. All bars indicate the
mean ± SEM, and *indicates p < 0.05. M; month after aneurysm induction.
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clonal anti-phospho NF-kappaB p65 (ser536) antibody
(Cell Signaling Technology, Danvers, MA, USA), rat mo-
noclonal anti-TNF-alpha antibody (Lifespan Bioscience,
Seattle, WA, USA), goat polyclonal anti-MCP-1 antibody
(Santa Cruz Biotechnology, Dallas, TX, USA), rabbit poly-
clonal anti-COX-2 antibody (Cayman Chemicals, Ann
Arbor, MI, USA), rat monoclonal anti-F4/80 antibody
(Abcam, Cambridge, UK).
Macrophage count
Macrophages were defined as cells positive for F4/80
staining in immunohistochemistry. The number of in-
filtrated macrophages was calculated within 10000 um2
around the dome of induced aneurysms (wild-type; n = 7,
TNFR1-deficient mouse; n = 5).
Quantitative real-time PCR analysis
RNA purification from the ring of Willis of mice 5
months after aneurysm induction (n = 4 in wild-type
and 3 in TNFR1-deficient mice) and subsequent reverse
transcription were performed using a RNeasy Fibrous
Tissue Mini Kit (QIAGEN, Hilden, Germany) and aHigh Capacity cDNA Reverse Transcription Kit (Life
Technologies Corporation, Carlsbad, CA, USA), respect-
ively, according to the manufacturers’ instructions. For
the quantification of gene expression, PCR reactions
were performed using the LightCycler 480 system with a
SYBR Premix Ex Taq II (Takara Bio Inc., Shiga, Japan),
using the expression of beta-actin as an internal control.
The following primers (forward and reverse, respec-
tively) were used in experiments: 5′-tctgcagccatttccttctc
tcc-3′ and 5′-aaaggcctccattgaccagagc-3′ for COX-2, 5′-
atgtctggacccattccttcttgg-3′ and 5′-tcccaatgagtaggctgga-
gagc-3′ for MCP-1, 5′-gctcgttgccaatagtgatgacc-3′ and
5′-cgtgcgtgacatcaaagagaagc-3′ for beta-actin.
Quantification of TNF-alpha protein content
The TNF-alpha protein content of intracranial arteries
with aneurysm induction was examined using multiplex
suspension array techniques, according to the manufac-
turer’s instructions. Briefly, intracranial arteries were col-
lected from 6 rats at each indicated time period after
aneurysm induction, and total protein was purified by
Bio-Plex Cell Lysis Kit (Bio-Rad, Hercules, CA, USA).
TNF-alpha protein content was then quantified by Bio-Rad
Figure 2 Suppression of IA formation in TNFR1-deficient mice.
(A) Incidence of IAs in wild-type (WT), TNFR1-heterozygous (hetero),
and TNFR1-deficient (KO) mice. IA was defined as a lesion with
disrupted internal elastic lamina by Elastica van Gieson staining. The
number of mice used for each genotype is shown in parentheses.
*indicates p < 0.05. (B) Systemic blood pressure in each genotype
(WT, wild-type mouse; Het, TNFR1-heterozygous mouse; KO, TNFR1-
deficient mouse) after aneurysm induction. Systemic blood pressure
(SBP, systolic blood pressure; MBP, mean blood pressure) was
measured by the tail-cuff method. All bars indicate the mean ± SEM.
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tem (Luminex, Tokyo, Japan) for detection, and DNASIS
Plex version 2.5 (HitachiSoft, Tokyo, Japan) for analysis,
according to the manufacturer’s instructions.
Measurement of TNF-alpha converting enzyme (TACE)
activity
The total protein from intracranial arteries after aneu-
rysm induction was purified by Complete M Lysis kit
(Roche, Basel, Switzerland) according to the manufactu-
rer’s instructions (n = 4 in each group). Each experiment
used 25 ug of protein. Total protein and the fluorescence-
labeled synthetic substrate for TACE (5-FAM-Ser-Pro-
Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Lys; BioMol,
Plymouth, PA, USA) were incubated in buffer containing
50 mM Tris–HCl (pH 7.4), 25 mM NaCl and 4% glycerol
for 1 h at 37°C. Enzyme activity was evaluated based
on the increase in fluorescence at 535 nm (excitation
485 nm).Statistical analysis
Data are shown as the mean ± SEM, and 2 groups were
statistically compared using the Mann–Whitney U test.
Statistical comparisons among more than 2 groups were
conducted using the Kruskal −Wallis test followed by
the Steel −Dwass test. The incidence of IAs was analyzed
by Fisher’s exact test. A p value smaller than 0.05 was de-
fined as statistically significant.
Results
Increased TNF-alpha content in IA lesion in a rat model
In this study, we used the rodent model of IAs to examine
the contribution of TNF-alpha signaling to IA formation.
In this model, IA was induced through increased he-
modynamic stress, a trigger of IAs in humans [15-17],
loaded on the bifurcation sites of intracranial arteries.
Three months after aneurysm induction, IA, defined as a
lesion with disrupted internal elastic lamina, was induced
at the right ACA-OA bifurcation in all rats.
The immunoreactivity of TNF-alpha was remarkably
increased in IA lesions compared with control intracra-
nial arteries, especially in endothelial cells and the outer
membrane, and the difference in relative intensity of po-
sitive signals in IA walls was statistically significant (n = 3
in each group, p = 0.049) (Figure 1A). Consistent with
these results, the content of TNF-alpha in the intracra-
nial artery, examined by multi-suspension array, was sig-
nificantly increased in rats with advanced stage IAs three
months after aneurysm induction (0 months, 39.4 ±
7.2 pg/mg total protein; 0.5 months, 37.0 ± 4.8 pg/mg total
protein; 1 month, 27.3 ± 3.0 pg/mg total protein; 3 months,
75.2 ± 6.1 pg/mg total protein; n = 6 in each group,
0 months compared to 3 months, p = 0.0497; 0.5 months
compared to 3 months, p = 0.0497; 1 month compared to
3 months, p = 0.020) (Figure 1B). TNF-alpha is released
from the cytoplasmic membrane through shedding, by the
action of TACE. We therefore examined the activity of
TACE in intracranial arteries including IA lesions, from a
rat model using labeled synthetic substrate. As a result, in
intracranial arteries from rats with aneurysm induction,
the activity of TACE was significantly increased compared
to control rats, suggesting up-regulation of TNF-alpha
production in IA lesions, consistent with increased TNF-
alpha content in IA lesions (0 months, 1.00 ± 0.36-fold,
n = 4; 3 months, 2.78 ± 0.71-fold, n = 4; 0 months com-
pared to 3 months, p = 0.028) (Figure 1C).
Suppression of IA formation due to TNFR1 deficiency
Next, to clarify the involvement of TNF-alpha signaling
in IA formation, we used mice deficient in its receptor,
TNFR1, based on the finding that TNFR1 was abundantly
expressed in intracranial arteries (data not shown). As a
result, 15 out of 22 wild-type mice, 1 out of 7 TNFR1-
heterozygous, and 1 out of 8 TNFR1-deficient mice, had
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dence of IA was significantly suppressed in TNFR1-
heterozygous and TNFR1-deficient mice compared
with wild-type mice (wild-type compared to TNFR1-
heterozygous, p = 0.026, wild-type compared to TNFR1-
deficient, p = 0.012) (Figure 2A), suggesting a critical role
for TNF-alpha-TNFR1 signaling in IA formation. Because
IA formation in the mouse model was greatly influenced
by systemic blood pressure, we confirmed the indepen-
dence of genotypes from systemic blood pressure after
aneurysm induction (systolic blood pressure: wild-type
mice, 115.0 ± 10.3 mmHg, n = 8; TNFR1-heterozygous
mice, 113.0 ± 9.0 mmHg, n = 7; TNFR1-deficient mice,
112.3 ± 8.6 mmHg, n = 8; mean blood pressure: wild-type
mice, 77.3 ± 7.2 mmHg, n = 8; TNFR1-heterozygous mice,
78.1 ± 9.8 mmHg, n = 7; TNFR1-deficient mice, 74.8 ±
3.9 mmHg, n = 8) (Figure 2B).
Suppression of inflammatory responses due to TNF-
alpha-TNFR1 signaling deficiency
Previously, we demonstrated the crucial role of inflam-
matory responses in IA formation [10,11,19,21,22]. In
this process, NF-kappaB activation and subsequent en-
hancement of macrophage infiltration into intracranial
arteries via NF-kappaB mediated-induction of MCP-1, a
major chemoattractant of macrophages in affected sites,
are essential for IA formation [10,11,19,21,22]. We there-
fore analyzed whether TNF-alpha-TNFR1 signaling defi-
ciency would attenuate this process.
First, we examined the activation of NF-kappaB in IA
lesions by immunohistochemistry to detect the phos-
phorylated form of the NF-kappaB p65 subunit (Serine
536 residue), and confirmed the suppression of NF-
kappaB activation under TNFR1 deficiency (Figure 3A).
Next, we confirmed the suppression of MCP-1 and
COX-2, which is a target gene of NF-kappaB signaling
and also the crucial factor for IA formation [19,21],
under TNFR1 deficiency, by both immunohistochemistry
and quantitative real time (qRT)-PCR, and the differences
between the two groups were statistically significant (im-
munohistochemistry: COX-2, wild-type compared to
TNFR1-deficient mice, p = 0.021, n = 4 in each group;
MCP-1, wild-type compared to TNFR1-deficient mice,
p = 0.043, n = 4 in each group; qRT-PCR: COX-2, wild-type
compared to TNFR1-deficient mice, p = 0.034, n = 4 in
wild-type and 3 in TNFR1-deficient mice; MCP-1, wild-
type compared to TNFR1-deficient mice, p = 0.034, n = 4 in
wild type and 3 in TNFR1-deficient mice) (Figure 3B, C).
Consistent with the suppression of MCP-1 in IA lesions
from TNFR1-deficient mice (Figure 3B), the infiltration
of macrophages into IA lesions was significantly inhib-
ited in TNFR1-deficient mice (wild-type mice, 5.00 ±
0.31 cells, n = 7; TNFR1-deficient mice, 1.40 ± 0.68 cells,
n = 5; p = 0.0061) (Figure 3D).Taken together, these results suggest a crucial role for
TNF-alpha-TNFR1 signaling in IA formation, by regula-
ting inflammatory responses through the induction of
NF-kappaB activation and subsequent macrophage infil-
tration into intracranial arteries.Discussion
In this study, we first revealed increased TNF-alpha con-
tent in IA lesions during IA formation and progression.
Second, we clarified a crucial role for TNF-alpha-TNFR1
signaling in IA formation by regulating inflammatory re-
sponses via NF-kappaB activation, using TNFR1-deficient
mice. Based on these experimental findings, we propose
TNF-alpha-TNFR1 signaling as a potential therapeutic
target for IAs.
A degenerative change in the tunica media is the his-
tological feature of IA walls. Because the degenerative
change in the tunica media in IA walls decreases arterial
stiffness and, as a natural consequence, raises the pro-
bability of rupture, the mechanisms regulating the de-
generation of media must be understood. In a previous
study, the authors revealed the contribution of TNF-
alpha to the phenotypic modulation of vascular smooth
muscle cells, a major cell component of media [23].
They also demonstrated that TNF-alpha signaling shifted
the phenotype of cultured vascular smooth muscle cells
from contractile to synthetic, and induced the expres-
sion of pro-inflammatory factors, MCP-1, MMP-9, and
IL-1beta [23]. The involvement of TNF-alpha signal-
ing in phenotypic modulation and vascular wall alter-
ation in vivo, after increased hemodynamic stress, was
also clarified [23]. Combining these findings with the
results presented here, it appears that the TNF-alpha-
TNFR1 signaling cascade is a suitable therapeutic tar-
get for IAs in order to prevent rupture.
In this study, as well as previous studies using human
specimens [6,12-14,23], the contribution of the TNF-
alpha-TNFR1 signaling cascade to IA formation, progres-
sion, and possibly rupture, is revealed. Based on these
findings, blocking the TNF-alpha-TNFR1 signaling cas-
cade has great potential as a strategy for treating IAs. The
TNF-alpha-TNFR1 signaling cascade is involved in the pa-
thogenesis of other inflammatory diseases, such as rheu-
matoid arthritis. In rheumatoid arthritis, the inhibition of
TNF-alpha-TNFR1 signaling by anti-TNF-alpha antibody
or soluble TNF receptor has been established as an effect-
ive treatment for patients [24]. Given the effectiveness of
TNF-alpha blockers in inflammatory settings, these drugs
are good candidates for the treatment of IAs. However, as
these drugs are expensive, and IAs have a high incidence
in the general public and require a long treatment period,
cheaper alternative drugs should be developed to inhibit
TNF-alpha-TNFR1 signaling.
Figure 3 Suppression of inflammatory responses in IA walls resulting from defective TNFR1 signaling. (A) Immunohistochemistry to
detect the phosphorylated form of the NF-kappaB p65 subunit (p-p65) in IA walls located at right anterior cerebral artery-olfactory artery bifurcations in
wild-type and TNFR1-deficient (TNFR1 KO) mice. Immunohistochemistry for anti- smooth muscle alpha actin (SMA) was used to indicate the media of
IA walls. Bar = 50 um. (B) Immunohistochemistry for COX-2 (upper columns), or MCP-1 (lower columns), and SMA (red color) in IA walls of wild-type
and TNFR1 KO mice. Bar = 50 um. In the right panels, the relative intensities of positive signals of COX-2 and MCP-1 in IA walls from the left panels are
shown. The number of mice used is shown in parentheses. *indicates p < 0.05. All bars indicate the mean ± SEM. (C) mRNA expression of COX-2 and
MCP-1 in wild-type and TNFR1 KO mice from quantitative real-time (qRT)-PCR analysis. n = 4 for wild-type and 3 for TNFR1 KO mice. *indicates p < 0.05.
All bars indicate the mean ± SEM. (D) The number of macrophages, F4/80-positive cells, in IA walls of wild-type and TNFR1 KO mice. All bars indicate
the mean ± SEM. The number of mice used is shown in parentheses. *indicates p = 0.0061.
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In this study, we used rodent models of IA through in-
creased hemodynamic stress to investigate the contributionof TNF-alpha-TNFR1 signaling to the pathogenesis of IA
formation and progression. We confirmed an increase
in TNF-alpha content in IA lesions in rat models during
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IA formation by inhibiting inflammatory responses in IA
walls such as NF-kappaB activation, MCP-1 induction,
and macrophage infiltration. These results suggest a cru-
cial role for TNF-alpha-TNFR1 signaling in IA formation
and progression.
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